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Mycobacterium tuberculosis continues to cause devastating levels
of mortality due to tuberculosis (TB). The failure to control TB
stems from an incomplete understanding of the highly specialized
strategies that M. tuberculosis utilizes to modulate host immunity
and thereby persist in host lungs. Here, we show that M. tuber-
culosis induced the expression of indoleamine 2,3-dioxygenase
(IDO), an enzyme involved in tryptophan catabolism, in macro-
phages and in the lungs of animals (mice and macaque) with active
disease. In a macaque model of inhalation TB, suppression of IDO
activity reduced bacterial burden, pathology, and clinical signs of
TB disease, leading to increased host survival. This increased pro-
tection was accompanied by increased lung T cell proliferation,
induction of inducible bronchus-associated lymphoid tissue and
correlates of bacterial killing, reduced checkpoint signaling, and
the relocation of effector T cells to the center of the granulomata.
The enhanced killing of M. tuberculosis in macrophages in vivo by
CD4+ T cells was also replicated in vitro, in cocultures of macaque
macrophages and CD4+ T cells. Collectively, these results suggest
that there exists a potential for using IDO inhibition as an effective
and clinically relevant host-directed therapy for TB.
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There is an urgent need to improve antitubercular treatmentstrategies. Tuberculosis (TB) continues to result in close to
two million deaths worldwide on an annual basis, and is the
single biggest killer of AIDS patients (1). Additionally, ∼10% of
newly diagnosed patients exhibited disease with some resistance
to anti-TB drugs, ranging from multidrug-resistant to extensively
drug-resistant TB (2). The failure to control TB stems from the
lack of relatively poor understanding of both pathogenesis and
the host factors that contribute to the susceptibility of TB dis-
ease. However, nonhuman primates (NHPs) recapitulate the
complete breadth of the lung pathology and granulomatous re-
sponses that are emblematic of human disease (3). The granu-
loma is the site of host–Mycobacterium tuberculosis interactions,
which either result in acute infection or the control of infection
in a latent state (4). M. tuberculosis modulates these immune
interactions to inhibit mycobacterial killing and therefore pro-
mote long-term survival of the bacilli.
The expression of indoleamine 2,3-dioxygenase (IDO) is dra-
matically enhanced in macaque granulomata (5). IDO catabolizes
Tryptophan (Trp) to kynurenine (Kyn) and other metabolites, and
acts to suppress the immune response, particularly the CD4+
T cell production of IFN-γ (6). Induction of host IDO is a nascent
strategy to starve pathogens of Trp, an essential amino acid (7).
However, M. tuberculosis can synthesize its own Trp de novo (8),
potentially an adaption for its survival during Trp catabolism by
IDO in host phagocytes. Therefore, IDO production has little
effect on mycobacterial metabolism and yet impacts protective
host immune responses.
Here we demonstrate that increased IDO1 expression corre-
lates with higher bacterial burden. Furthermore, IDO is partic-
ularly enriched in the macrophage-rich inner layer of the
granuloma (5). This spatial expression may prevent lymphocytes,
which are predominant in the external layers of the granuloma,
from reaching the infected phagocytes, and this inhibition may
further promote bacterial survival. We therefore hypothesize
that the highly organized granulomas seen in NHPs and humans
may be advantageous toM. tuberculosis due to this spatial exclusion
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of immune-protective lymphocytes. As such, the IDO pathway
represents a potential target for host-directed therapy (HDT) to
augment the control of TB.
Inhibitors of IDO activity [e.g., 1-methyl-tryptophan (1-MT, D-
1MT)] are being evaluated as anticancer drugs. In this study, we
demonstrated that D-1MT–mediated IDO inhibition resulted in
somewhat increased M. tuberculosis killing, improved clinical
signs of disease, increased lymphoid follicles and proliferation
of pulmonary lymphocytes, and was associated with a drastic
reorganization of the granuloma that allowed lymphocyte
trafficking into the macrophage-tropic internal layers. These
results lend significant credence to the utilization of IDO in-
hibitors as an HDT strategy adjunctive to anti-M. tuberculosis
chemotherapy (9).
Results
IDO1 Is Expressed in a M. tuberculosis Burden-Dependent Manner in
Infected Phagocytes and Experimental Hosts. We first studied
whether IDO levels are induced in a M. tuberculosis burden-
dependent manner. We found that IDO expression is induced
in M. tuberculosis-infected murine (C3HeB/FeJ) bone marrow-
derived macrophages (BMDMs) (Fig. 1A) and rhesus macaque
BMDMs (Fig. 1B and Fig. S1) in vitro and in lungs of M. tu-
berculosis-infected C3HeB/FeJ mice (Fig. 1 C and D). Further-
more, IDO expression levels were highly correlated with lung
CFUs (P = 0.02, r2 = 0.68) (Fig. 1E). We have recently shown
that most animals with latent TB infection (LTBI) that were
subsequently coinfected with simian immunodeficiency virus
(SIV), reactivated (10). In coinfected animals, IDO levels largely
Fig. 1. Expression of IDO1 in in vitro as well as in vivo experimental models ofM. tuberculosis infection. IDO levels detected by qRT-PCR at 0 (gray) and 24 h
(red) after M. tuberculosis infection relative to uninfected BMDMs from three biological replicates (A) C3HeB/FeJ mice (70) and (B) rhesus macaques (71). The
average relative expression (2−ΔΔCt) of IDO in C3HeB/FeJ mice lungs at weeks 8, 12–20, and 24 in respect to postday 1 (base line)M. tuberculosis-infected lungs
by qRT PCR (C) and microarray (D) (70). Linear regression (r2 = 0.68, P < 0.05) plot of IDO1 expression correlates to bacillary load in C3HeB/FeJ mice lungs at
weeks 8 and 12 obtained is from C (E). IDO expression in the lung of rhesus macaques with ATB (dark blue bars), LTBI (intermediate blue bars), chemo-
therapeutic treatment of ATB (light blue bars), or nonpathogenicM. tuberculosis infection (dark and light purple bars) by qRT-PCR (F) and microarray (G). IDO
expression in M. tuberculosis-infected (dark blue bars), LTBI-coinfected SIV lungs either exhibited a reactivation (dark brown bars) or nonreactivation phe-
notype (light brown bars) (10). IDO expression in lungs of rhesus macaques infected with nonpathogenic MtbΔdosR (dark purple bars) or MtbΔsigH (light
purple bars) (11, 13). Linear regression (r2 = 0.48, P < 0.0001) plot of IDO expression correlates to bacterial burdens in the lungs of rhesus macaques with ATB
(24–37 d postinfection) and LTBI (166–180 d postinfection) (H). Expression of Trp biosynthetic pathway genes in ATB (dark blue) and LTBI (light blue) animals
(I) and their linear regression with IDO expression levels in ATB and LTBI animals (r2 = 0.41, P < 0.005) (J). Data are means ± SEM, *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.001 using (A, B, and I) Student’s t test, (E, H, and J) linear regression analysis, or (C, D, F, and G) one-way ANOVA.



























correlated with M. tuberculosis burdens (Fig. 1 F and G). Animals
with TB exhibited an ∼20- to 40-fold IDO induction relative to
baseline, whereas the expression was unperturbed in animals that did
not reactivate (Fig. 1 F andG) with high degree of concordance (P <
0.0001, r2 = 0.48) (Fig. 1H). To effectively demonstrate IDO in-
duction as a correlate of M. tuberculosis burden, we measured its
expression in macaques receiving chemotherapy. Daily oral admin-
istration of moxifloxacin, ethambutol, and pyrazinamide, a
multidrug-resistant regimen in humans, reduced IDO1 expression
relative to untreated controls (Fig. 1 F and G). Consistent with the
above findings, low IDO expression was observed in animals infected
with nonpathogenic M. tuberculosis (Mtb) strains MtbΔsigH and
MtbΔdosR (11–13) (Fig. 1 F and G). Lungs of animals infected with
a high dose of MtbΔsigH mutant had reduced IDO levels (Fig. 1 F
and G), which again demonstrates that IDO levels were driven
by uncontrolled M. tuberculosis replication. Unlike MtbΔsigH,
MtbΔdosR exhibits only partial attenuation, and adaptive immune
responses are required for its control (13), likely explaining the in-
termediate expression of IDO in animals infected with MtbΔdosR
(Fig. 1G). Hence, IDO is expressed in an M. tuberculosis burden-
dependent manner. Concomitantly, the expression of the M. tuber-
culosis trpA, trpB, trpD, and trpY genes was induced in macaques with
active TB (ATB) relative to LTBI (Fig. 1I). Thus, Trp biosynthesis is
switched on in M. tuberculosis in vivo and correlates with host ex-
pression of IDO (Fig. 1J).
D-1MT Treatment Improves the Clinical Outcomes and Reduces Lung
Tissue Pathology. Macaques recapitulate several aspects of human
TB including ATB and LTBI (5, 11–26), HIV coinfection-mediated
reactivation TB (10, 15), as well as immune protection (5, 21). We
tested the importance of IDO signaling in vivo in acutely infected
macaques by treating the animals with D-1MT, a specific inhibitor
of IDO activity. Treatment was initiated 1 wk afterM. tuberculosis
infection (Fig. S2). The progression of TB was significantly altered
in treated macaques, as reflected by clinical outcomes (Fig. 2).
Whereas all of the control animals had to be killed within 5 wk of
M. tuberculosis infection, D-1MT–treated animals survived until
8 wk, exhibited significantly delayed kinetics, and lower levels of
serum C reactive protein (CRP) compared with controls (Fig. 2A).
Similarly, treated animals exhibited limited weight loss over time
compared with control animals (Fig. 2B). This finding was con-
sistent with the low bacterial burdens detected in treated animals
(Fig. 2 C–E). CFUs were determined from bronchoalveolar lavage
(BAL) in two groups each at week 1 (the time when treatment was
initiated), week 3 (i.e., 2 wk after treatment), and at the end point,
at which time M. tuberculosis CFUs were also assessed in the lung
tissues. The control animals exhibited significantly higher M. tu-
berculosis burdens (P < 0.05) in BAL at week 3 and in the terminal
lung samples compared with the D-1MT–treated animals. BAL
data are shown for at least three animals (Fig. 2C). However, the
CFU levels in the BAL did not differ between the two groups at
week 1, before initiating treatment, indicating that the initial in-
fections were similar (Fig. 2C). The total bacterial burdens in
terminal lungs (Fig. 2D) and bronchial lymph node (BLN) (Fig.
2E) were significantly lower in D-1MT–treated animals than in the
control animals (>1 log, P < 0.05). The bacterial burdens were
also lower in liver, kidney, spleen in D-1MT–treated animals than
controls (Fig. 2E). D-1MT–treated animals presented with fewer
granulomas (Fig. 2F) relative to control animals (Fig. 2G) and
exhibited significantly lower (P < 0.005) lung pathology (Fig. 2H).
Hence, animals treated with D-1MT not only had better clinical
outcomes (Fig. 2 A and B) and reduced pathology (Fig. 2 F and
H), but also exhibited reduced bacterial burdens (Fig. 2 C–E).
Together, these results underscore our contention that, although
active TB developed in all animals, the disease in D-1MT–treated
animals progressed more slowly and to a lesser extent.
D-1MT Treatment Reduces the IDO Enzymatic Activity. The central area
of the BAL cytospin that contained regular, monolayer-distributed
cells, as confirmed by H&E staining (Fig. S2), was used for Kyn
staining on samples obtained from D-1MT–treated and control an-
imals at week 3. Kyn is one of the end products of IDO enzymatic
activity. Numerous studies have implicated it in the immunosup-
pressive function of this signaling pathway (27). It is also known to be
a ligand for the aryl hydrocarbon receptor signaling pathway (28).
Confocal microscopy revealed greater levels of Kyn accumulation in
controls, relative to D-1MT–treated animals (Fig. 3A). Furthermore,
quantification revealed a highly significant (P = 0.0001) fourfold re-
duction in the average number of Kyn+ cells in D-1MT–treated
animals (Fig. 3B). We also quantified absolute levels of Kyn and Trp
in the plasma, a second measure of IDO activity by ELISA using
pure standards, and calculated the Kyn/Trp ratio as an indirect
measure of IDO activity (Fig. 3C). The two groups had virtually in-
distinguishable Kyn/Trp ratios at week 1 (i.e., before the initiation of
treatment). In week 3 plasma samples, however, a significantly dif-
ferent (P < 0.001) Kyn/Trp ratio was observed between two groups.
Both results suggest that D-1MT treatment inhibits IDO enzyme
activity (> 95% reduction) (Fig. 3C). The effect of D-1MT on IDO
enzymatic activity could also be observed in the treated group of
animals at later stages (up to week 8) during the infection (Fig.
S2B). These results establish that the changes in disease progression
in D-1MT–treated animals were correlated with inhibition of IDO.
Effect of the in Vivo Modulation of IDO Signaling on T Cell Phenotype.
We phenotyped mononuclear cells isolated from dematricized
lung and BAL from the end point. Using these samples, we
assessed temporal changes in both T cell numbers and T cell
phenotypes in the lungs. BAL data at the end point was com-
pared between two groups (Fig. 3 D–H), as previously described
(10–13, 16, 20–23). The quantification of memory subsets was
established for T cell populations based on CD28 and CD95
coexpression for which a representative flow cytometry plot and
Fig. 2. Clinical, microbiology and pulmonary pathology
measures of infection and disease in control and D-1MT–
treated macaques. Linear regression of serum CRP (μg/mL)
between two groups (A). Linear regression of weight
change over the course of time (weeks postinfection) be-
tween two groups: D-1MT–treated (orange circle), control
(gray circle) (B). (C–E) Bacterial burdens detected by CFU
assay in BAL (C), per gram of lung tissues (D), and per
gram tissue for each BLN, spleen, liver, and kidney (E).
Subgross H&E staining of lung sections fromD-1MT (F) and
control animals (G). (Scale bars, 250 μm.) Morphometric
measure of TB-related total lung pathology (H). At least three
systematic random microscopic fields from each lung, repre-
senting all lung lobes, from at least two of the animals in
every group, were used for the morphometric analysis of
histopathology. Data aremeans± SEM, *P< 0.05, **P< 0.01,
***P< 0.001 using (C) one-wayANOVAwith Bonferroni post
correction or (D, E, and H) Student’s t test; ns, not significant.
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gating strategy are shown in Fig. S3. Comparisons were also made
to T cell phenotypes in peripheral blood (Fig. S4) and immune cell
numbers in blood, BAL, and lung (Figs. S4 and S5). We observed
significant differences in the percentage of these cells that
expressed the highly specific proliferation marker Ki67 (29–32).
Thus, the percentage of both central memory (Fig. 3 D and F) and
effector memory (Fig. 3 E and G) cells was higher in BAL as well
as lungs of D-1MT–treated animals compared with controls, with
enhanced CD4+ TCM proliferation, detected by Ki67, in the
treated group (Fig. 3H). Moreover, this difference in T cell pro-
liferation between the two groups could also be observed in pe-
ripheral blood (P = ∼0.05) (Fig. S4). Similarly, the Ki67+ status of
central memory CD4+, CD8+, and effector memory CD8+ cells
was also significantly enhanced (P < 0.05) in the peripheral blood
of D-1MT–treated animals relative to control animals (Fig. S4).
However, no differences were observed between the two groups of
animals in the total number of CD4+ or CD8+ cells in blood (Fig.
S4 E–G), in BAL before or after D-1MT treatment (Fig. S5 A–D)
or in the lung (Fig. S5 E–G), except that significantly higher levels
(P < 0.05) of CD8+ TEM cells were present in D-1MT animals at
the end point (Fig. S5H). As it is well established that Trp ca-
tabolism orchestrated by IDO1 inhibits T cell proliferation (33,
34), mediated directly by end products of this pathway (34), we
propose that inhibition of T cell proliferation by IDO1 is one of
the primary mechanisms of Trp catabolism-mediated immune
dysfunction in the context of M. tuberculosis infection.
D-1MT Induces Inducible Bronchus-Associated Lymphoid Tissue Formation.
We next analyzed the potential effects of D-1MT treatment on
inducible bronchus-associated lymphoid tissue (iBALT) forma-
tion. The presence of granuloma-associated iBALT is correlated
with protection from M. tuberculosis infection (13). Paraffin-
embedded lung samples collected at the time of necropsy were
assayed for iBALT by histopathology and immunofluorescence
staining with CD3 (detects T cells) and CD20 (detects B cells)
antibodies, followed by confocal microscopy and image analysis
(13). The presence of B cells and their follicular organization were
greater in D-1MT–treated animals (Fig. 3I) relative to control
animals (Fig. 3J). The total number of B cells enumerated in
multiple lesion sections of lung was significantly higher (P =
0.0013) for D-1MT–treated animals compared with controls (Fig.
3K). These results further support our previous observations that
protection from M. tuberculosis infection directly correlates with
the presence of granuloma-associated iBALT (10, 13, 19, 22).
IDO Inhibition in Vivo Causes Broad-Spectrum Improvement in
Granuloma Function. We assessed if IDO inhibition improved
the function of granulomas in effectively controlling M. tuberculosis
Fig. 3. Assessing the IDO enzymatic activity in M. tuberculosis-infected macaques in vivo and its impacts on T and B cell phenotypes. BAL staining 3 wk after
M. tuberculosis-infection; red, Kyn; blue, nuclei; gray, DIC marked with white arrowheads pointing toward the lining that appears a cell membrane indicates Kyn
deposition within a cell. [Scale bars, 100 μm (Upper); 20 μm (Lower).] (A) Kyn quantification (B) and Kyn/Trp ratio by ELISA (C). In A, images are shown at different
scale with more number of cells in a field from D-1MT–treated animals. Phenotype of memory T cells in BAL and lung samples at necropsy with respect to pro-
liferation as measured by Ki67 positivity in D-1MT–treated (orange) and controlanimals (gray) (D–H). A representative flow-density plot from lungs of memory T cells
expressing Ki67 (H). Costaining with CD20 and CD3 exhibits iBALT in D-1MT–treated (I), control animals (J): red, CD20
+ B cells; green, CD3+ T cells; blue, macrophages.
[Scale bars, 20 μm (I, Left and Right, and J, Right); 40 μm (I, Middle and J, Left).] White box indicates CD3+ T cells (I) and CD20+ B cells (J) found in iBALT follicle.
Quantification of B cells in the multiple lesions from both groups: D-1MT–treated (orange circle) and control (gray circle) (K) (means ± SEM). *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.001 using a (B and K) Student’s t test or (C) two-way ANOVA or (D–G) repeated-measures t test.



























(Fig. 4 and Figs. S6 A–D and S7 A and B). Host genes involved in
the proinflammatory cytokine storm and especially the NF-κB
network were induced to higher levels in controls relative to
D-1MT–treated animals, highlighting the acute nature of infection
in that group (Fig. 4A, two left-most heat maps). The expression of a
majority of type I IFN signaling/neutrophil response genes, which
are well-characterized biomarkers of active TB (35), was also higher
in controls (Fig. 4A). Supervised analyses further revealed signatures
of elite granuloma performance in D-1MT–treated animals. These
responses were associated with a reduction in T cell inhibitory sig-
naling, including the immune checkpoint inhibitors LAG3, CTLA4,
IDO1, CD27, and CD244, and so forth, all of which exhibited lower
expression in D-1MT–treated animals (Fig. 4A). LAG3 expression
was detected in CD3+ as well as CD3− T cells (Fig. S7 A and B).
LAG3 is expressed on populations of activated T cells, such as Tregs
and NK cells (23, 36), and in the lymphocyte-rich outer layer of the
granulomata during ATB (23), and contributes to the reprogram-
ming of the Th1 response (37). Such an environment is likely to be
supportive of M. tuberculosis persistence rather than its clearance.
Concomitantly, the lungs of treated animals presented with a sig-
nature of enhanced T cell stimulation and function: for example,
increased CCR5 [involved in cross-talk between T cells and mac-
rophages via its ligands CCL16 and CCL8 (38, 39)], CCL25 [in-
volved in T cell development (40)], and NFATC [involved in the
maturation of robust anti-M. tuberculosis Th1 responses (41)] ex-
pression. This was accompanied by increased growth receptor and
calcium signaling, signifying a rapidly proliferating thymocyte pop-
ulation (Fig. 4A). In contrast, the lungs of control animals exhibited
correlates of T cell dysfunction and exhaustion (Fig. 4A), in agree-
ment with other recent work (42). These results indicate that T cell
dysfunction and exhaustion in control animals leads to better M.
tuberculosis survival than in treated animals (P < 0.05) (Fig. 2E).
The lungs of D-1MT–treated animals concomitantly also
expressed more intense antimicrobial responses, characterized
by induction of certain CD8+ T cell genes: for example, CTSB
(increased by ∼1.3-fold) and other related cathepsins essential for
CD8 cytotoxic function (43). In the B cell module, BTK, which is
involved in promoting B-cell development and maturation (44),
was enhanced 3.3-fold by D-1MT treatment. On the other hand,
ETS1, which is involved in down-regulating B cell differentiation
(45), was induced by 21-fold in controls compared with D-1MT–
treated lungs. Thus, the robust expression of antimicrobial genes,
such as cathelicidin antimicrobial peptide, cathepsin B, lysosomal
vATPase, and RAB39, in D-1MT–treated animals (Fig. 4A) fur-
ther underscored our point that suppression of IDO elicits a
stronger host response during infection. Most of these genes were either
down-regulated or their expression was reduced in control animals.
Several other genes that have positive effects on T cells, either by
differentiation or activation, were also induced in D-1MT–treated
animals relative to controls (Fig. 4A). On the other hand, genes that
negatively affect T cells, either through regulating effector function
or survival, were more highly expressed in control animals. The
higher expression of genes in the apoptosis module in the treated
group was particularly interesting; despite higher T cell pro-
liferation (∼46% in D-1MT–treated animals compared with ∼12%
in control animals) (Fig. 3), the total T cell counts were in-
distinguishable between the two groups (Fig. S4 E–G). The ex-
pression of NR4A1, which encodes a regulator that promotes T cell
apoptosis (46, 47), was induced in the lungs of D-1MT–treated
animals (Fig. 4A). These microarray results suggest that the highly
proliferative thymocytes being recruited to the lungs of D-1MT–
treated animals exhibited apoptosis-mediated turnover.
In addition to several pathways related to T cell proliferation,
differentiation, and apoptosis, the induction of type I IFNs (Fig.
4A) in BAL confirms the lung data (Fig. 4B) from D-1MT–
treated animals. Selected results were validated by qRT-PCR,
which confirmed that IDO1 mRNA levels were reduced (by
∼50%) in the BAL (Fig. S6B) and lungs (Fig. 4B) of D-1MT–
treated animals compared with control animals. Whereas the
expression of IDO2 and IFN-γ was not statistically different in
both BAL (Fig. S6C) and lungs (Fig. 4B) in treated animals, rel-
ative to untreated animals, the IFN-γ levels approached near
significance (P = 0.0582) between the two groups in BAL. By RT-
PCR, the expression of type I IFN, IFN-β was significantly in-
duced (P < 0.05) both in the lungs (Fig. 4B) and BAL (Fig. S6D)
of the D-1MT–treated animals. However, we did not detect an
induction in the IFN-inducible downstream genes—such as IFIT-
1, IFIT-2, IFI44, and so forth—either by microarrays (Fig. 4A) or
RT-PCR (Fig. S6 F–H). D-1MT treatment not only alters the host
immune responses, but presented with differential B cell and
apoptosis signatures (Fig. 4A). Treatment also correlated with
altered tissue remodeling, as represented by the up-regulation of
several MMPs, IL-8, PAK3, and TIAM (13, 48) (Fig. 4A). IL-8 not
only augments the ability of leukocytes to phagocytose and kill
bacilli, but it also governs T cell recruitment, thus potentially
enhancing immunity to M. tuberculosis infection (49). Tran-
scriptomics suggested greater T cell apoptosis in D-1MT–treated
animals, and so to verify this we immunostained for the T cell
receptor CD3 and performed a TUNEL assay. Immunostaining
revealed that animals treated with D-1MT exhibited greater T cell
apoptosis (Fig. 4 D and E), explaining why there was a comparable
number of T cells in both groups (Figs. S4 and S5), despite the
higher T cell proliferation in treated animals (Fig. 3 and Fig. S4).
Inhibition of IDO Permits the Reorganization of the TB Granuloma and
Allows CD4+ T Cells Access to the Lesion Core. The expression of
IDO in M. tuberculosis-infected macaques primarily occurred in
the myeloid (inner half) ring of the granuloma and colocalized
with the CD68+/CD163+ signal. This result reinforced our belief
that antigen-presenting cells (APCs) in the lung express IDO in
response to acute M. tuberculosis replication. We hypothesized
that this may lead to the reorganization of the tuberculoma, such
that the CD4+ T cells in the lymphoid (outer half) ring are ex-
cluded from the pathogen-rich regions, thereby facilitating greater
survival and persistence of M. tuberculosis.
Next, since the expression of IDO specifically occurs in the inner
myeloid ring of the granulomata, we tested the translocation of
T cells to the center of the lesion (necrotic center) in lung granu-
loma of D-1MT–treated and control animals (Fig. 5). Toward this
end, we studied if the demarcation between the necrotic center and
the lymphocytic layer was more disrupted in the lesions derived from
IDO-inhibitor–treated animals relative to untreated animals where
it was well defined (Fig. 5 C and D). We found drastic and signifi-
cant differences (P < 0.05) in the number of CD4+ T cells present in
the inner half of the center of the lesions derived from D-1MT–
treated relative to untreated animals (Fig. 5 D and E). Thus, rela-
tive to control animals, the total number of CD3+ T cells per lesion
and their migration from the lymphocytic layer to the necrotic
center of granuloma were higher in D-1MT–treated animals (Fig.
5E). These results clearly indicate that IDO signaling affects T cell
infiltration into the necrotic centers of granulomas. However,
quantification of cells staining positive for IDO indicated that the
numbers in the macrophage layer were indistinguishable between
the groups (Fig. S7). Additionally, anti-M. tuberculosis staining
revealed a higher number of bacilli in the lung lesions derived from
control- in comparison with D-1MT–treated animals (Fig. 6).
Greater bacillary signal was present in the necrotic center in the
treated animals compared with the macrophage-rich layer in control
animals (Fig. 6). The effector role of CD8+ T cells in the control of
M. tuberculosis infection has recently been described (10). In the
present study, we determined that the proliferation of central and
effector memory CD8+ T cells was significantly enhanced in
D-1MT–treated animals than controls (Figs. 3 and 6). Therefore,
we sought to better characterize the phenotype of the lymphocytes
migrating toward necrotic lesions (Fig. 5E). Approximately 60% of
these cells in lesions from D-1MT–treated animals were found to
be positive for granzyme B, which was significantly greater than in
controls (Fig. 6). A correlation between the frequency of granzyme-
expressing T cells and control of human pulmonary TB has been
previously described (50). Granzyme B expression on lymphocytes
migrating to the lesion core upon IDO inhibition suggests that the
latter controls tissue remodeling events. We speculate that IDO
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inhibition permits lymphocytes with cytotoxic phenotype to migrate
to the center of the tuberculoma and assist in the control of
M. tuberculosis replication. It is possible that some of these cells may
be classic CD8+, but the role of other CD3+ populations, such as
NKT cells and mucosal-associated invariant T cells, cannot be ruled
out. These results indicate that intragranulomatous T cell function
is radically altered by D-1MT–mediated inhibition of IDO activity.
We conclude that blockade of IDO signaling leads to signifi-
cantly better control of M. tuberculosis infection and reduces the
signs of TB disease by promoting the proliferation of memory T cell
subtypes and by enhancing the ability of granulomas to kill M. tu-
berculosis. Because of the possibility that disruption of granuloma
following D-1MT treatment might lead to increased dissemination
of M. tuberculosis to extrapulmonary tissues, we performed CFU
assays in BLN, liver, kidney, and spleen at the time of necropsy. The
CFU counts in these organs revealed lesser bacterial burdens than
controls; however, these numbers were statistically insignificant
in liver, kidney, and spleen but drastically reduced in BLN in
Fig. 4. Impact of inhibiting IDO on lung gene expression. Selected modules derived from significantly enriched pathways based on the method described else-
where (70) in BAL microarray datasets are shown. The horizontal colored bar on top of each module for a category represents a range in gene-expression mag-
nitude in logarithmic base2. Heat-map clusters: “black” to “yellow” to “red,” lower (fold-change ∼1.5 cut-off) to higher expression (A). The change in gene
expression (2−ΔΔCt) by RT-PCR (B), cytokine assay (C) in lung homogenates of D-1MT–treated (orange) and control animals (gray) relative to uninfected lung samples
as base line. GAPDH was used as an internal reference. Bars with no statistics shown are nonsignificant between two groups (e.g., IFN-γ) (P = 0.3381) (C).
Immunofluorescence-based detection of T cell apoptosis by TUNEL assay. The arrowheads (white) in each magnified image indicate apoptotic cells [scale bars, 20 μm
(Right); magnification, 20× (Left)] (D). Data obtained by counting multiple fields with T cells positive for TUNEL staining using a Leica confocal microscope (Leica
Microsystems) (E). The data (means ± SEM) from animals from both groups were used for analysis; *P < 0.05, ****P < 0.001 using a Student’s t test.



























comparison with controls (Fig. 3F). Thus, CFU measurements ruled
out that disruption of granuloma by D-1MT treatment does not
cause an increase in bacterial dissemination to extrapulmonary tis-
sues, but indeed, these animals have over all lesser bacterial burdens.
Inhibition of IDO Signaling in Macrophage: CD4+ T Cell Cocultures
Restricts Mycobacterial Growth. We cocultured M. tuberculosis-
infected rhesus macrophages where IDO expression had been
silenced, with M. tuberculosis-specific CD4+ T cells in vitro,
and measured bacterial burden (Fig. S1) used were from
rhesus macaques with acute TB infection. The siRNA specifi-
cally affected IDO1 (Fig. S1 F and J) and not IDO2 (Fig. S1 F
and K) expression. IDO1 silencing resulted in a greater control
ofM. tuberculosis replication when macrophages were cocultured
with CD4+ T cells but not in macrophages alone (Fig. S1E). The
silencing of IDO1 resulted in increased levels of IFN-β (Fig. S1 F
Fig. 5. Extensive relocalization of T cells to the internal regions of
the macaque granulomata after inhibition of IDO-signaling. H&E
staining of a representative lesion from D-1MT–treated (Left) and
control (Right) groups is shown (A). A schematic representation of the
granulomata shown in A is drawn in B, distinctly differentiating the
lymphocytic and macrophage layers from the necrotic center.
The expression of IDO was measured as a function of its presence in
either of the three intragranulomatous compartments (necrotic,
macrophage, or lymphocytic layer) by immunostaining; IDO (green),
CD3 (red), and nuclei (blue) (C). A magnification of the white
square area in C is shown in D, with white arrowheads pointing to
CD3+ cells in red. The number of CD3+ cells (E, Upper) as well as
total nuclei (E, Lower) in multiple granulomata in D-1MT–treated
(orange with circular data points) and control (gray with triangle
data points) animals enumerated in the lymphocytic, macrophage,
and necrotic center compartments are shown. For quantification,
10 fields from each compartment were counted under a fixed
magnification (corresponding to an area of 0.05 mm2) using a
multispectral imaging camera (CRi Nuance). The data are means ±
SEM, *P < 0.05, **P < 0.01, ***P < 0.001 using a Student’s t test.
[Scale bars, 20 μm (C, also applies to A and B); 5 μm (D).]
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and L), while the expression of IFN-γ (Fig. S1 F and M) and the
internal control GAPDH (Fig. S1F) was not perturbed.
Discussion
M. tuberculosis utilizes the host granulomatous response to per-
sist in the face of strong immunity (51), by modulating both innate
(52) and adaptive (53) immune responses. The fate of M. tuber-
culosis infection is decided in the granuloma; some lesions affect
elite control ofM. tuberculosis replication via enhanced killing, but
others fail, resulting in uncontrolled replication and spread.
Therefore, the potential to modulate granulomatous responses
in favor of bacterial killing by enhancing natural immunity using
HDT exists (54, 55). These HDT approaches can channel the
chronic immune dysregulation displayed by granulomas that fail,
resulting in counterproductive lung pathology, into productive
responses characterized by sterilization of granulomas.
M. tuberculosis can overcome the restriction imposed by IDO and
the resulting Trp insufficiency, by biosynthesizing this amino acid
(8). IDO potently suppresses CD4+ T cells via a variety of mecha-
nisms, including limiting their proliferation (56), induction of im-
munoregulatory APCs, and by promoting the differentiation of
Th0 cells into Tregs (57, 58). Thus, high IDO activity has been
correlated with pathogen burden and sepsis during infection (59),
especially with intracellular pathogens (60), includingM. tuberculosis
(61). Here, inhibition of IDO activity by a potent yet safe inhibitor in
macaques led to a slightly better control of M. tuberculosis replica-
tion, and somewhat reduced pathology and disease severity, ac-
companied by increased proliferation of CD4+ and CD8+ memory
and effector populations, and the inhibition of lung marker T cell
exhaustion and dysfunction. This was associated with reorganization
of the granulomata, with T cells otherwise present in the peripheral
region of lesions being able to gain greater access to the core region.
It has recently been shown that mycobacterial infection results
in the reprogramming of macrophages in the granuloma to a
flattened, epithelial phenotype (62). This results in macrophage
interdigitation and tighter granulomas. Inhibition of canonical
epithelial pathways in the zebrafish model of Mycobacterium
marinum infection resulted in the dysregulation of the granu-
loma, along with immune cell access to the lesion core, and re-
duced bacillary burdens (62). These results, taken together with
our study, suggest that the ability of pathogenic mycobacteria to
replicate within host lungs is intricately linked to lesion organization,
and disruption of this process represents an attractive future strategy
for the control of TB.
Our results have implications both for the fundamental un-
derstanding of why granulomas are unable to achieve their full
potential duringM. tuberculosis infection and for providing clues to
Fig. 6. Granuloma performance in D-1MT–treated and control animals. Immunohistochemistry staining of lung sections for CD3+ T cells; (A) Ki67 (red), (B)
granzyme B (red) with CD3 in green and nuclei (TOPRO3) stained in blue (A and B) andM. tuberculosis (red) staining (C). Multiple granzyme B+ cells can be observed
in the necrotic center of granuloma from D-1MT–treated animals and are marked with white arrowheads. The far-right images in each panel are close-ups of the
boxed region. (Scale bars, 150 μm.) The total number of cells positive for both CD3 and Ki67 as well as CD3 and granzyme B in A and B, respectively, as well as total
nuclei in each panel were counted in multiple granulomata for each group and plotted. The graphs (far right in each panel) show percentages of cells positive for
Ki67 (A) and granzyme B (B). The H&E staining of a representative lung lesion from D-1MT–treated (Upper) and control animals (Lower). [Scale bars, 20 μm (C, H&E);
150 μm (C, immunostaining).] A schematic representation of the granulomata and demarcation (L, lymphocytic layer; M, macrophage layer; N, necrotic center) in C is
shown as described and is also applicable to A and B. The far-right image in C is the close-up of the boxed region and the graph shows the enumeration of bacilli in
both groups (C). ***P < 0.001, ****P < 0.0001 using a Student’s t test. Data are means ± SEM, D-1MT treated (orange circle), controls (gray circle).



























likely targets of productive HDT against TB, including IDO. These
results suggest that the complex and highly ordered architecture of
the primate (and human) lung tuberculoma may in fact be bene-
ficial to the pathogen by preventing contact between T cells and
pathogen-containing APCs. It may, however, be possible to alter
granuloma architecture by inhibiting IDO signaling, and thereby
allowing T cells access to the lesion core while also fostering the
development of the follicular organization of B cell-containing
iBALT. Such lesions appeared to overcome checkpoint inhibition
and T cell dysfunction, greatly promoting bacterial killing.
Inhibition of IDO signaling in vivo, as well as in vitro, en-
hanced the expression of the type I IFNs, although the expres-
sion of all type I downstream genes (e.g., IFIT1, IFIT2, IFIT3,
and so forth) was not induced. These results are not surprising,
given that IDO can be induced by both IFN-γ as well as type I
IFN. This regulation of IDO by type I vs. type II interferons is
context- and cell-type–dependent (63). It appears that type I IFN
plays a major role in triggering IDO expression in primate al-
veolar macrophages in the context of M. tuberculosis infection,
and therefore, inhibition of IDO enzymatic activity likely causes
induction of type I IFN gene expression via feedback (63, 64).
Whereas type I IFN is an important antiviral mechanism (65), its
induction correlates with increased lung pathology and exacer-
bated disease upon M. tuberculosis infection (66). As such, ap-
proaches targeting type I IFN signaling have been successfully
attempted in experimental models of TB (66). Our data suggest
that the concurrent silencing of IDO signaling and type I IFN sig-
naling could lead to a more profound control of TB in macaque
(and human) lungs. Furthermore, testing the potential of such HDT
alone, as well as concurrently with anti-TB chemotherapy, could
pave the way for future clinical applications. Our results suggest that
therapeutic strategies aimed at eliminating or reducing the levels of
cells with IDO induction followingM. tuberculosis infection, such as
myeloid-derived suppressor cells in the lung, may also result in re-
duction of TB. Finally, we have not discussed as part of this report
the conundrum that IDO expression on nonhematopoetic cells
following M. tuberculosis infection may indeed have a protective
effect for the host, as has been shown in the murine model (67).
Moreover, several novel IDO inhibitors are being generated (e.g.,
Indoximod), and it may be possible in future studies to test if they
are preclinically superior to D-1MT in suppressing IDO activity.
Materials and Methods
In Vivo. Ten rhesus macaques were infected with a high dose of M. tuber-
culosis CDC1551 (∼200 CFU) via the aerosol route, as described previously
(10–16, 23). Five animals were randomly chosen to be in the treatment
group and were D-1MT–treated daily, via the oral route with an IDO enzy-
matic activity inhibitor, D-1MT (45 mg/kg body weight) 1 wk after M. tu-
berculosis infection. The remaining animals served as controls.
NHPs, Infection, Sampling, Killing, and Clinical Pathology. All 10 animals were
negative for tuberculin skin test (TST) before infection, but tested positive 3 wk
after M. tuberculosis infection. Blood and BAL were collected before and after
M. tuberculosis infection and during the time-course of D-1MT treatment till
necropsy. CFUs were measured in BAL 1 wk after M. tuberculosis infection and
every 2 wk thereafter until the end point. Lung pathology was determined as
described previously (11, 15). CFUs were also measured in lung and lymph node
tissues derived at necropsy, as described previously (10–16, 23). Humane end points
were predefined in the animal-use protocol and applied as a measure of reduction
of discomfort as described earlier to kill animals as necessary (10, 11, 13). The
Tulane National Primate Research Center Institutional Animal Care and Use Com-
mittee and the Tulane Institutional Biosafety Committee approved all procedures.
All animal procedures were performed in strict accordance with NIH guidelines.
Immunostaining and Confocal Microscopy. H&E histology, immunostaining, and
confocal microscopy were performed on formalin-fixed, paraffin-embedded
tissues, as previously described (5, 10–13, 15, 19, 22, 23, 68–71). Staining for
Kyn was performed on fixed (4% formaldehyde) BAL cytospun frozen slides
using a Kyn-specific polyclonal antibody (ImmuSmol). For preparation of frozen
BAL slides, 0.1–0.5 million BAL cells were cytospun on a positively charged glass
slides (Inform; PerkinElmer) at 700 × g for 7 min at room temperature, followed
by washing two times with PBS (1× solution; Thermo Fisher Scientific). Slides
were kept for evaporation of residual liquid for 10 min followed by addition of
4% PFA (room temperature) and incubation for overnight and stored in −80 °C.
ELISA. Trp and Kyn were quantified in blood plasma samples from all animals
before infection (baseline) and everyweek thereafter until necropsy, using a Trp
and Kyn ELISA kit strictly as per the manufacturer’s instructions (ImmuSmol).
Flow Cytometry. Flow cytometry was performed on whole blood, BAL, and
lung samples from all animals, as previously described (10–13, 16, 20, 21, 23,
26). Briefly, memory subsets were established for T cell populations based on
CD28 and CD95 coexpression (72), as previously described (11), and sub-
divided based on CD3+, CD28+, CD95+ subsets being defined as central
memory, and CD3+, CD28−, CD95+ being defined as effector memory. Vari-
ous antibodies and their amount used for staining are described in Table S2.
Cytokine Assay. Cytokine assays were performed in lung samples derived at
time of necropsy from D-1MT–treated and control animals, as well as from
naïve (not infected with M. tuberculosis and untreated) lungs (as baseline)
following the procedures described earlier (11, 23, 68–71).
Quantitative Real-Time RT-PCR and Transcriptomics. Total RNA from BAL
obtained at baseline and 3-wk after M. tuberculosis infection of two rep-
resentative animals from each group, was amplified using MessageAmp II
aRNA Amplification Kit (Thermo Fisher Scientific) and processed for micro-
array and qRT-PCR, as described previously (11, 13).
In Vitro Culturing.Monocyte derivedmacrophages (MDMs)were generated from
macaque blood and cocultured with CD4+s, as described previously (73). A subset
of MDMs was treated with IDO1-specific siRNA 24 h before M. tuberculosis-
infection (multiplicity of infection = 10:1) (Table S1) to inhibit IDO1 expression,
as described previously (71). Samples were collected at 0 and 24 h post-
infection (71) and used for CFU assay, qRT-PCR, and immunocytochemistry.
Statistics. Unless otherwise stated, statistical analyses were performed with
Prism v7 (GraphPad). For statistics, either Mantel–Cox (log-rank) survival
analysis, Student’s t test, or a t test with repeated-measures or two-way or
one-way ANOVA with Bonferroni multiple comparisons was performed.
When required, a goodness-of-fit in linear regression was performed for the
statistical analysis between two groups.
More details can be found in SI Materials and Methods.
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SI Materials and Methods
In Vivo. Ten rhesus macaques were infected with a high dose of
Mycobacterium tuberculosis CDC1551 (∼200 CFU) via the aerosol
route, as described previously (1–8). Five animals were randomly
chosen to be in the treatment group and were D-1MT–treated
daily, via the oral route with an IDO enzymatic activity inhibitor,
D-1MT (45 mg/kg body weight) after week 1 of M. tuberculosis
infection. D-1MT has been previously used to assess the impact of
IDO on SIV disease progression in macaques (9). The remaining
five animals served as controls.
NHPs, Infection, Sampling, Killing, and Clinical Pathology. All animal
procedures were approved by the Institutional Animal Care and
Use Committee of the Tulane National Primate Research Center
(TNPRC) and were performed in strict accordance with NIH
guidelines. The TNPRC is accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care and is
routinely monitored by the US Department of Agriculture. In-
fection was performed as described previously using an aerosol
exposure modality specifically configured for macaques (1–8). All
10 animals were negative for tuberculin skin test before in-
fection, but tested positive 3 wk after M. tuberculosis infection.
Blood and BAL samples were collected before and after M. tu-
berculosis infection and during the time-course of D-1MT
treatment till necropsy. Serum CRP, a marker for systemic in-
flammation, correlated with extent of disease in both groups
based on the parameters described previously (1–3). CFUs were
measured in BAL 1 wk after M. tuberculosis-infection and every
2 wk thereafter until and including the end point. Lungs were
stereologically sectioned and pathology was determined as de-
scribed previously (3, 6). CFUs were also measured in lung and
lymph node tissues derived at necropsy, as described previously
(1–8). For various assays, lung samples obtained from naïve,
TST-negative rhesus macaques from the TNPRC colony were
used as baseline. Humane end points were predefined in the
animal-use protocol and applied as a measure of reduction of
discomfort, as described earlier to kill animals as necessary (1–
3). Macaques were killed based on Institutional Animal Care
and Use Committee-approved guidelines. To minimize any ex-
perimental variation, tissues, blood, and BAL samples collected
at each time point and during necropsy were immediately pro-
cessed without storage for downstream applications, such as flow
cytometry, CFU determination, and so forth.
Immunostaining and Confocal Microscopy. H&E histology, immu-
nostaining, and confocal microscopy were performed on
formalin-fixed, paraffin-embedded tissues as previously de-
scribed (1–3, 6–8, 10–16). Staining for Kyn was performed on
fixed (4% formaldehyde) BAL cytospun frozen slides using a
Kyn-specific polyclonal antibody (ImmuSmol). For preparation
of frozen BAL slides, 0.1–0.5 million BAL cells were cytospun on
a positively charged glass slides (Inform; PerkinElmer) at 700 × g
for 7 min at room temperature followed by washing two times
with PBS (1× solution; Thermo Fisher Scientific). Slides were
kept for evaporation of residual liquid for 10 min followed by
addition of 4% PFA (room temperature) and incubation for
overnight. On the following day, slides were wrapped in a foil
and stored in −80 °C until used. All of the operations were
performed at room temperature inside the BSL3 laminar flow.
For quantification of LAG-3, Ki67, Granzyme B, and M. tuber-
culosis in the individual lesions, 10–15 fields from multiple
granulomas were counted under a fixed magnification using a
multispectral imaging camera (CRi Nuance) and plotted.
ELISA.Trp and Kyn were quantified in blood plasma samples from
all animals before infection (baseline) and every week thereafter
until necropsy using Trp and Kyn ELISA kit strictly as per the
manufacturer’s instructions (ImmuSmol). The Trp and Kyn
values were extrapolated from respective known standards pro-
vided in each kit and the numeric ratio (Kyn/Trp) was calculated
and plotted using GraphPad.
Flow Cytometry. Flow cytometry was performed on whole blood,
BAL, and lung samples from all animals as previously described
(1–3, 5, 7, 8, 16–19). Briefly, memory subsets were established
for T cell populations based on CD28 and CD95 coexpression
(20) as previously described (3), and subdivided based on CD3+,
CD28+, CD95+ subsets being defined as central memory, and
CD3+, CD28−, CD95+ being defined as effector memory. Vari-
ous antibodies and their amount used for staining are described
in Table S2.
Cytokine Assay. Cytokine assays were performed in lung samples
derived at time of necropsy from D-1MT–treated and control
animals, as well as from naïve (not infected with M. tuberculosis
and untreated) lungs (as baseline) following the procedures de-
scribed previously (3, 8, 10, 12, 15, 16) with minor modifications.
Briefly, lung homogenates were prepared in the lysis Buffer
[500 mM Tris·HCl, 0.1% (wt/vol) SDS, 0.15% sodium deoxy-
cholate, 1× protease inhibitor mixture, 1× phosphatase inhibitor
mixture (Roche)]. For preparation of lung homogenates, 1 mL
lysis buffer per 0.2-g tissue was used. Lung homogenates were
filtered with 0.22-μm filters (Millipore) before use in cytokine
assay using Cytokine Monkey Magnetic 29-Plex Panel kit (Ther-
mo Fisher Scientific), essentially as described previously (10).
Quantitative Real-Time RT-PCR and Transcriptomics. For host-
transcriptomics, total RNA isolated from BAL obtained at the
preinfection (∼1-wk before infection, baseline) and 3-wk afterM.
tuberculosis-infection of two representative animals from each
group was subjected to RNA amplification using MessageAmp II
aRNA Amplification Kit (Thermo Fisher Scientific) and pro-
cessed for microarray and qRT-PCR, as described previously (2,
3). The microarray datasets relative to baseline (as above) were
subjected to statistical analysis using ANOVA, as previously
described (16). The impact of gene-expression profiles in ani-
mals from both groups was compared using Ingenuity Pathway
Analysis (Ingenuity Systems). The gene families with significant
overrepresentation were selected for supervised clustering and
pathway analyses using DAVID and as described elsewhere (2,
3). The genes of a significantly overrepresented pathway (from
above) were used to generate modules. The qRT-PCR was
performed on subset of genes on microarray datasets and for the
detection of Trp biosynthetic gens of M. tuberculosis (for primer
sequences, see Table S1) in triplicates on RNA derived from
four animals in both ATB and LTBI groups, following the
method described previously (2, 21).
In Vitro Culturing. Macaque whole blood was collected in EDTA
tubes (S-Monovette Sarstedt) and monocytes isolated by
Histopaque-1077 (Sigma) density gradient centrifugation. MDMs
from these samples were used in a coculture model with autol-
ogous CD4+ T cells (22). A negative-selection process that in-
volves MACS (magnetic-activated cell sorting) with the NHP
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CD4+ T cell Isolation Kit (Miltenyi Biotec) was used to isolate
CD4+ T cells as described previously (22). A subset of MDMs
was treated with IDO1-specific siRNA 24 h before M. tubercu-
losis-infection (multiplicity of infection = 10:1) (Table S1) to
inhibit IDO1 expression as described previously (16). Samples
were collected at 0 and 24 h postinfection (16) and used for CFU
assay, qRT-PCR, and immunocytochemistry.
Statistics. Unless otherwise stated, statistical analyses were per-
formed with Prism v7 (GraphPad). For statistics, either Mantel–
Cox (log-rank) survival analysis, Student’s t test or a t test with
repeated measures or two-way or one-way ANOVA with Bon-
ferroni multiple comparisons was performed. When required, a
goodness-of-fit in linear regression was performed for the sta-
tistical analysis between two groups.
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Fig. S1. Analysis of the role of IDO1 during M. tuberculosis-infection using MDMs:CD4+ T cells in an in vitro coculture model. (A–C) A representative IFN-γ
response of CD4+ T cells. The CD4+ T cells from peripheral blood mononuclear cells prepared from whole blood were used to measure their functional profile,
unstimulated (A), and Staphylococcal enterotoxin B (SEB)-stimulated (C) cells are negative and positive controls; M. tuberculosis cell wall-stimulated (B).
Schematic design (D) of coculture experiment (E–M). MDMs proliferated for 120 h, followed by IDO1 silencing before M. tuberculosis-infection (D). CFU
measurements at 24 h (E). IDO1 silencing (F and J). Confocal microscopy (G–I) showing immunocytostaining of CD4 T cells (white, G and H) MDMs (green), nuclei
(blue), and intracellular M. tuberculosis (red) marked with white arrowheads. A representative image of an infected macrophage withM. tuberculosis (stained
in red and shown with black arrowheads in I) associated with T cell indicated with a white arrowhead is shown within a dotted yellow circle in a MDMs:CD4+
T cell coculture experiment (I). (Scale bars, 20 μm.) IDO1 silencing, expression of IFN genes, and bacterial killing in MDMs in the presence of CD4+ T cells that
were derived from rhesus macaques with acute TB infection (E–M). The qRT-PCR on RNA samples derived at 24 h afterM. tuberculosis infection to detect IDO1
Legend continued on following page
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(F and J), IDO2 (F and K), and interferons; IFN-β (F and L) and IFN-γ (F and M). The gel-electrophoresis–based visual detection of various expression levels of
genes; IDO1, IDO2, IFNB, and GAPDH measured by RT-PCR.M. tuberculosis-infected MDMs (blue bar), M. tuberculosis-infected MDMs with IDO1-specific siRNA
(light blue bar), M. tuberculosis-infected MDMs cocultured with T cells (dark red bar), and M. tuberculosis-infected MDMs with IDO1-specific siRNA and T cells
(light red bar). Growth reduction in number ofM. tuberculosis bacilli (means ± SEM) in coculture was statistically significant using one way ANOVA, *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.001. Three independent experiments performed in triplicates with samples derived from six rhesus macaques were used for
analysis. [Scale bars, 40 μm (G and H); 20 μm (I).]
Fig. S2. (A) In vivo study design. A total of 10 Indian rhesus macaques were infected with M. tuberculosis CDC1551. Five macaques were treated daily with
D-1MT (45 mg/kg body weight) via the oral route, beginning 1 wk after M. tuberculosis infection. M. tuberculosis-infected but untreated animals served as
controls. Blood and BAL were collected every 2 wk after M. tuberculosis-infection till killing when a complete necropsy was performed for the collection of
various tissues and samples for microbiological, biochemical and immunological analyses. (B) Measurement of IDO activity in BAL. Numeric Kyn/Trp ratio in
plasma samples between weeks 5–8 after M. tuberculosis infection or at necropsy of D-1MT–treated (orange), in comparison with the end point-only time
point for the control animals (gray). All five animals in each group were included in the assay and analyses. Data are means ± SEM, **P < 0.01 using a Student’s
t test. (C and D) H&E staining of BAL cytospin. BAL cytospin samples stained for H&E are shown with vast majority of macrophages present (blue arrows) with
few lymphocytes (LC, black arrows) and polymorphonuclear (PMN) leukocytes (white arrows) that are marked in both groups. (Scale bars, 10 μm.)
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Fig. S4. Flow cytometry based detection of T cell proliferation and T cell counts in blood. (A–D) T cell proliferation. The percentages of CD4+ T cell central
memory (TCM) and CD8+ T cell effector memory (TEM) measured by Ki67 positivity in blood collected at necropsy from both groups; D-1MT (orange) and
control (gray). The differences approaching significance (P = 0.058) using a Student’s’ t test are shown for CD4+ TCM in both groups. The data are means ± SEM,
*P < 0.05, using a Student’s t test. The samples at necropsy of five animals each from D-1MT–treated and control groups were included in the analyses. (E–G)
T cell counts. Percentages of CD4+ effector and both CD8+ cell- and effector-memory cells with no significant differences (analyzed using Student’s t test)
obtained in D-1MT–treated and control animals are shown; ns, not significant.
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Fig. S5. Flow cytometry-based detection of T cell counts in BAL and lungs. (A–D) T cells counts in BAL. Percentages of T cells in BAL derived at necropsy of
D-1MT–treated (orange) and control animals (gray) are shown. The T cell frequencies with no statistical differences for CD4+ TCM (P = 0.0655), CD8+ TCM (P =
0.1568), CD4+ TEM (P = 0.0638), and CD8+ TEM (P = 0.1049) are shown between two groups of animals. The BAL samples at necropsy of five animals from each
group were included in the flow cytometry experiments and analyses. (E–H) T cell counts in lung. Percentages of T cells in BAL derived at necropsy of D-1MT–
treated (orange) and control animals (gray) are shown. The differences in T cell frequencies of CD4+ TEM, CD4+ TCM, and CD8+ TCM was insignificant and CD8+
TEM was statistically significant (*P < 0.02) between two groups using a Student’s t test. The lung samples at necropsy of five animals from each group were
included in the flow cytometry experiments and analyses. ns, not significant.
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Fig. S6. Transcriptomics in BAL. (A) Microarray-based detection of cytokine signaling pathways in BAL. Gene families with significant overrepresentation as
previously described (22), selected for supervised clustering and pathway analyses using DAVID are shown. RT-PCR (B–H). Relative expression (2−ΔΔCt) of IDO1
(B), IDO2 (C), and interferons, IFN-β (D), IFN-γ (E), IFIT1 (F), IFIT2 (G), IFI44 (H) detected at week 3 postinfection; D-1MT–treated (orange) and control animals
(gray). The data obtained are significant (*P < 0.05) for IFN-β or approaching significance for IFN-γ (P = 0.0582) or for IDO1 (P = 0.0570) and not IDO2, IFIT1,
IFIT2, or IFI44 using a student’s t test. The BAL samples of three animals from each group were included for the analyses.
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Fig. S7. Detection of LAG3 and IDO1 deposition in lungs by immunohistochemistry. Immunofluorescence based staining of LAG3 (green), CD3+ T cells (red),
and nuclei (blue) in lungs of D-1MT–treated and control-animals (A). The data obtained by counting multiple fields for cells positive for LAG3 between two
groups (orange, D-1MT–treated; gray, control) using Leica confocal microscope (Leica Microsystems) was plotted using GraphPad (B). The data are means ±
SEM, ***P < 0.0001 using a Student’s t test. Quantification of IDO deposition in the granulomata (C–E). Cells that stained positive for IDO1 in granulomata of
animals from two groups; D-1MT–treated (orange) and control (gray) were enumerated in the various compartments: the lymphocytic layer (C), macrophage
layer (D), and necrotic layer (E) (also see Fig. 5 for distribution of these layers within granuloma). The data obtained by counting IDO+ cells (C–E) in multiple
fields and granuloma were significant for the lymphocytic layer (P < 0.0001) and necrotic center (**P < 0.05) using a student’s t test, or these numbers were not
different in the macrophage layer in the lesions derived from two groups of animals. ns, not significant. (Scale bars, 20 μm.)
Fig. S8. Immunohistochemistry of lung sections derived from D-1MT–treated and control animals; IDO1 (green), CD3 (red), and nuclei (blue). [Scale bars,
20 μm (Upper); 40 μm (Lower).]
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Table S1. Primers and siRNA used in the study
Gene/siRNA Primer/siRNA sequence (5′-3′)
Rh IDO1 F GGTTTATGCAGACTGTGTCTTGGCA
Rh IDO1 R CTCCATCACGAAAGGAGAACAAAAC
Rh IDO2 F CAGATTCTCTGAAAGAACTTCCAGAT
Rh IDO2 R ACATGAGCTCGAAGCTGGTGAGC
Rh IFN-γ F GACTCGAATGTCCAACGCAAAGCA
Rh IFN-γ R CGACCTCGAAACATCTGACTCCTTT
Rh IFN-β F ACGCTGCATTGACCATCTATGAGA
Rh IFN-β R TTAGCAAGGAAGTTCTCCACAATAGT
Rh GAPDH F TCAAGAAGGTAGTGAAGCAGGCGT
Rh GAPDH R AAGAGTGGGTGTCGCTGTTGAAGT
Mtb trpE F GTACCGAATTCTGCGGGTAA
Mtb trpE R ACAATCGAAAAGTCCACTGC
Mtb trpD F GAGGTTGGGATCGGGTTCT
Mtb trpD R CCCGAGAAGATTGAACACGG
Mtb trpC F AATCGTTGGGTATGACAGCA
Mtb trpC R GTTAACGCCAATCACCTTGG
Mtb trpA F GCGGCATTGATTGGTTACTT
Mtb trpA R GGAACCCCGACTTCGATAAT
Mtb trpB F TAGGTGTTGAGTTGGGAAGG
Mtb trpB R AGCAAGCCAAACCATTTCG
Rh IDO1 siRNA sense GGAUAAAGGUCAUGGAGACUU
Rh IDO1 siRNA antisense GUCUCCAUGACCUUUAUCCUU
This table reports the sequences of oligonucleotides and macaque specific IDO1 Si-RNA used in qRT-PCR
and cell culture, respectively. The primers were designed from rhesus macaque-specific andM. tuberculosis-
specific genes. F, forward primer; R, reverse primer; Rh, rhesus.
Table S2. List of antibodies
Fluorochrome Antibody name Source Clone
Quantity used
per sample (μL) Catalog no.
FITC CD69 BD Biosciences FN50 20 555530
PerCP-Cy5.5 CD4 BD Biosciences L200 20 552838
APC CD8 BD Biosciences RPA-T8 10 555369
AL 700 CD3 BD Biosciences SP34-2 10 557917
APC-HY7 CD20 BD Biosciences 2H7 5 560853
BV421 CD95 BD Biosciences DX2 5 562616
BV510 Ki67 BD Biosciences B56 5 563462
BV711 CD28 BD Biosciences CD28.2 5 563131
PE CCR5 BD Biosciences 3A9 20 550632
The table summarizes the list of antibodies used for staining by flow cytometry experiments.
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